Ben Shelley's Stock Ratings

UBS Analyst

Ben Shelley is an analyst at UBS. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/31/2025

Overall Average Return

-8.98%

Smart Score

17.3%

Overall Average Return Percentile

22nd

Number of Ratings

4
Buy NowGet Alert
03/06/2025FLUTBuy Now
Flutter Entertainment
$228.8248.59%
Ben Shelley17%
$335 → $340MaintainsBuyGet Alert
01/28/2025FLUTBuy Now
Flutter Entertainment
$228.8246.4%
Ben Shelley17%
$320 → $335MaintainsBuyGet Alert
11/26/2024FLUTBuy Now
Flutter Entertainment
$228.8239.85%
Ben Shelley17%
$308 → $320MaintainsBuyGet Alert
11/08/2024FLUTBuy Now
Flutter Entertainment
$228.8233.73%
Ben Shelley17%
 → $306Initiates → BuyGet Alert

Recent Analyst Stock Rating News

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Growing Your Own Weed Could Land You In Jail In Washington State As Home Cultivation Bill Dies In House Committee
Lawmakers in Washington state have declined a move to allow adults to legally cultivate cannabis at home. House lawmakers failed to vote on House Bill 2194 from Representative Shelley Kloba before the 5 February deadline. The bill would have permitted home cultivation of up to four plants per person or 10 per household. Currently, growing cannabis for personal use without a medical card is a Class C felony. Those found guilty face up to five years in prison and a fine of up to $10,000. Washington became one of the first US states to legalise cannabis for recreational use back in 2012. However, efforts to extend legalisation to home-growing have faced opposition from those concerned about illegal sales and use by minors.
Cannabis Movers & Shakers: Pure Extracts, TGOD, MedMen, Gel Cap Concepts, KEY Investment, MediPharm
Here is a summary of the latest company shakeups within the cannabis industry.
Cannabis Movers & Shakers: MPXI, Benzinga, RespireRx, MedMen, Medipharm
Here comes another Tuesday, with the latest updates on leaderhip changes within the cannabis industry. MPXI Part Ways With David McLaren, Appoints Interim CFO
Janet Yellen's Testimony Makes A Good First Impression With Analysts
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved